Tofacitinib (trade names Xeljanz and Jakvinus formerly tasocitinib CP-690550) is a drug of the janus kinase (JAK) inhibitor class discovered and developed by Pfizer. It is currently approved for the treatment of rheumatoid arthritis (RA) in the United States and Russia and is being studied for treatment of psoriasis inflammatory bowel disease and other immunological diseases as well as for the prevention of organ transplant rejection.
This page contains content from the copyrighted Wikipedia article "Tofacitinib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
